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Abstract In recent years, Candida albicans infections
treatment has become a growing problem because, among
others, pathogenic strains are capable to develop resistance
to the administered drugs. The elaboration of rapid and
accurate method of resistance assessment is an important
goal of many studies. They aim to avoid inappropriate
dosage or drug choice, which may be life threatening in
case of severe candidiasis. Here we propose a new protocol
to predict C. albicans infections. The resistance prediction
is based on high-resolution melt (HRM) analysis of ERG11
gene, especially, at the particularly unstable regions. Two
statistically significant nucleotide polymorphisms were
detected among twenty-seven strains isolated from saliva,
one of which was silent mutation (Glu266Asp, Leu480-
Leu). We propose also HRM analysis as a convenient,
simple and inexpensive method of preliminary selection of
C. albicans DNA samples that vary in ERG11 nucleotide
sequence within presumed region. Taken together, our
study provides firm basis for the development of fast,
simple and reliable methodology for diagnosis of C. albi-
cans infections.
Introduction
Candida spp are opportunistic yeasts that normally inhabit
human skin, genitourinary and gastrointestinal tracts.
Under some conditions, Candida may overgrow and col-
onize mucosal and skin surfaces [5], which usually leads to
easily treated infections. However, in patients with
impaired immune system, severe candidiasis and life-
threatening systemic infections can develop. Among Can-
dida species, Candida albicans is the most frequent cause
of human infections.
Several different mechanisms of drug resistance have
been already described [4, 40]. Resistant Candida strains
may overexpress membrane transporters which are
responsible for drug removal from the cell [25, 28]. Efflux
pumps can also be more active in drug-resistant strains than
in susceptible ones [38]. Most commonly administered
antifungal drugs are azole compounds and the main azole
drugs target is lanosterol-14-a-demethylase, encoded by
ERG11. Point mutations in ERG11, as well as overex-
pression of this gene, are usually involved in the devel-
opment of resistance to azole-based drugs [6]. Mutations
that lead to amino acid substitution may cause changes in
the affinity of the enzyme for azole derivatives [6, 30, 41].
Thus, huge effort has been made to develop fast and reli-
able methods for detecting strains that bear mutations [1,
35, 39]. Most of these methods involve nucleic acid
amplification and gel electrophoresis [35].
Among numerous ERG11 mutations, both homozygous
and heterozygous nucleotide changes were reported to
correlate with azole susceptibility [6, 29, 41, 42]. A huge
progress in ERG11 mutations identification has been made
in recent years and it is well known now, which of them are
the most frequent and which are most probably involved in
azole resistance [24]. However, detailed drug-resistant
& Monika Caban
monika.a.caban@gmail.com
1 Cytometry Lab, Department of Molecular Biophysics,
Faculty of Biology and Environmental Protection, University
of Ło´dz´, Pomorska 141/143, 90-236 Ło´dz´, Poland
2 Biobank Lab, Department of Molecular Biophysics, Faculty
of Biology and Environmental Protection, University of
Ło´dz´, Pilarskiego 14/16, 90-231 Ło´dz´, Poland
3 Institute of Medical Biology, Polish Academy of Sciences,
Lodowa 106, 93-232 Ło´dz´, Poland
123
Curr Microbiol (2016) 73:172–182
DOI 10.1007/s00284-016-1039-3
mutation pattern of ERG11 gene is still desired. We sug-
gest that to achieve this aim, it is also important to consider
mutations that do not directly change amino acid compo-
sition of the enzyme, but may also correlate with resistant
phenotype, and thus may serve as convenient drug resis-
tance markers. Likewise, silent polymorphism in drug-re-
sistance transporter MDR1 gene (C3435T) was established
as a risk factor for non-clear cell renal cell carcinoma [34].
It has been also shown that (C3435T) polymorphism may
lead to the synthesis of protein product with different
structural and functional properties, in spite of unchanged
amino acid sequence [12]. Proposed molecular mechanism
of this phenomena is the existence of frequent and infre-
quent codons in mRNA which influence the translation
kinetics and temporal separation of folding events during
protein synthesis causes conformational and functional
differences of final protein [13]. Silent mutations in ERG11
gene of C. albicans occur with threefold higher frequency
then amino acid changing mutations [21].
HRM (High-Resolution Melt) analysis is a precise and
sensitive method, which can be successfully used for
identification of species [20]. This technique allows to
discriminate amplicons that differ in single nucleotide
(single-nucleotide polymorphisms) as they generate vari-
ous shapes of melting curves when heated after amplifi-
cation [15]. Therefore, we propose HRM analysis as a
rapid and robust method of preliminary scanning ampli-
cons which allows to minimize the number of samples to
be sequenced. Thus, it may contribute essentially to save
money, time and labor, especially in case of diagnostic
laboratories. Here we applied a recent PCR-based tech-
nique, high-resolution melting (HRM) analysis, to deter-
mine differences in ERG11 sequence isolated from various
C. albicans strains and searched for ERG11 polymor-
phisms that are statistically significant in drug-resistance
prediction.
Materials and Methods
Control Strains and Clinical Isolates
Three strains used as control strains were as follows:
Ca11r—C. albicans (ATCC 10231) and Ca12r—C. albi-
cans (ATCC 60193) and Ca1r—clinical C. albicans strain
identified by MALDI. Seven clinical isolates came from
vaginal candidiasis patients (Ca1V–Ca7V) and have been
kindly provided by Dr. Agata Karowicz-Bilin´ska (Medical
University of Lodz). 28 strains (Ca1s–Ca82s) were isolated
from the saliva of healthy volunteers (Bioethics Committee
agreement no. 6./KBBN-UŁ/II/2014). Clinical strains were
isolated on yeast extract–peptone–dextrose (YEPD) agar
plates supplemented with chloramphenicol. Then, they
were directly identified as C. albicans species using chro-
mogenic culture media (chromID Candida, bioMe´rieux),
HRM and sequence analysis of ITS2 regions (data not
shown). All strains were stored at -70 C as stocks in 8 %
DMSO. Strains were cultured for 24 h at 37 C in YEPD-
agar containing 2 % glucose, 2 % peptone, and 1 % yeast
extract.
Antifungal Susceptibility Testing
The susceptibility of reference and vaginal strains to anti-
fungal drugs was tested according to the modified NCCLS
M27-A microdilution procedures. Briefly, 1:1 dilutions of
fluconazole (FCA), ketoconazole (KET), miconazole
(MIC), itraconazole (ITR), amphotericin B (AMB), and 5
flucytosine (5FC) were prepared in 96-well plates in RPMI
medium, frozen and thawed when needed. 24-h yeast cul-
ture in YPD medium was washed in RPMI medium and
2.5 9 103 cells mL-1 were seeded on a 96-well plate.
IC50 was determined spectrophotometrically after 48 h of
incubation. To determine the saliva isolates, susceptibility
ATB FUNGUS3 (BioMerieux) tests were used according
to manufacturer’s instructions.
DNA Isolation
Genetic material was extracted with modified Harju yeast
genomic DNA isolation method [8]. Briefly, liquid culture
of yeast was pelleted. Cell pellets were resuspended in
200 ll of lysis buffer [2 % Triton X-100, 1 % SDS,
100 mM NaCl, 10 mM Tris–HCl, 1 mM EDTA (pH 8.0)].
Cell suspension was heat shocked on ice bath followed by
95 C water bath twice. Samples were then vortexed with
chloroform, centrifuged and the aqueous layer was trans-
ferred to the ice-cold 96 % ethanol. After 5 min incuba-
tion, the probes were centrifuged and the supernatant was
removed. DNA was washed with 70 % ethanol, pelleted,
air-dried, resuspended in 30 ll of sterile water and stored at
-20 C.
HRM Analysis
For HRM analysis, the whole ERG11 gene was divided to 9
regions, aprox. 300 bp each. Primers were designed so as
to obtain all specific PCR products at the same annealing
temperature. Sequences of primers used for amplification
are given in Table 1.
PCR was performed with Go Taq Master Mix (Pro-
mega), LCGreen (BioFire Diagnostics) and aprox. 0.2 lg
DNA template was filled up with water to reach 15 ll of
reaction mixture. HRM reactions were performed using the
Bio-Rad CFX96 real-time PCR system. The amplification
program was one cycle at 95 C (2 min) and 95 C (30 s),
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60 C (30 s), 72 C (15 s) 9 55 cycles followed by: 95 C
for 1 min, and 40 C for 1 min. Melting of amplicons was
conducted by rising the temperature from 67 C to 91 C
with an 0.2 C increase step. Melting curve analysis was
performed by BioRad Precision Melt Analysis Software
and verified visually.
PCR and DNA Sequencing
Whole ERG11 gene was amplified as two overlapping
parts, each amplified with a unique oligonucleotide primer
pair. Gene fragments were then sequenced from both ends
with the same primers. The first part primer pair used was
as follows: forward primer (50-AGACAAAGAAAGGG
AATTCAATC-30), reverse primer (50-TTGACCACCCA
TAAGAATACCA-30); the second part forward primer
(50-CGTGATGCTGCTCAAAAGAA-30), reverse primer
(50-AAATAACCAGTGGACAAAAACCAT-30). PCR was
carried out with Go Taq Master Mix (Promega) and the
amplification program was one cycle at 95 C for 3 min,
followed by 45 cycles at 95 C for 30 s, 58.1 C for 30 s,
and 72 C for 45 s. Amplicons had the length of approx.
250–300 bp, were verified by agarose gel electrophoresis
and were purified with a Wizard SV Gel and PCR Clean-up
System (Promega).
DNA reads (Eurofins MWG Operon, Germany; Institute
of Medical Biology of PAS, Poland) were screened for the
presence of ambiguous nucleotide signals.
Results
Candida albicans Strains Exhibit Various Resistance
to Antifungal Drugs
The susceptibility of reference strains and strains isolated
from vagina was determined with microdilution method.
MIC was defined as the 50 % inhibition of growth for 5
flucytosine and azole drug tests, and total inhibition of
growth for amphotericin B. From among nine C. albicans
strains tested, one (Ca5V) was classified as resistant to all
azole compounds tested (Table 2). Five strains (Ca1V,
Ca4V, Ca7V, Ca2V, Ca12r) have shown increased resis-
tance to azole drugs and 5-flucytosine as assessed by drug
concentration necessary for complete growth inhibition
(data not shown).
The growth inhibition of saliva strains was determined
visually on ATB FUNGUS3 tests after 24 h incubation
(Table 3). Visual readings for most strains did not allow to
establish MIC values as they showed very similar growth
in all azole drug concentrations. Fourteen strains were
classified as resistant (slight decrease in turbidity), and
eleven were susceptible (no growth), one strain (Ca21s)
was hard to classify (hazy growth). Strain Ca68s showed
sharp difference in growth ability as 16 mg/l of fluconazole
completely inhibited yeast growth, what is defined as sus-
ceptible dose-dependent according to NCCLS interpretive
guidelines. Amphotericin B and 5-flucytosine efficiently
inhibited growth of all strains.
HRM Analysis Allowed to Distinguish Five Variants
of ERG11 Gene Related to Drug Resistance
HRM analysis was conducted to verify the utility of this
method in analysis of C. albicans ERG11 gene profiles that
correlate with drug resistance. Whole sequence of C.
albicans ERG11 gene was analyzed as nine fragments.
PCR followed by HRM analysis of products was con-
ducted, which allowed to distinguish between different
genetic variants of reference strains and vaginal isolates
(Table 4). Initially, one to four variants/clusters of each
scan were determined among 9 DNA samples. Then, the
same patterns of 9 scans variants/clusters were classified as
gene variants and marked 1.–5.
Table 1 List of primers used for the amplification in HRM analysis
PCR product size (bp) Sequence of forward primer Sequence of reverse primer
Scan 1 268 50-AGACAAAGAAAGGGAATTCAATC-30 50-TGCCATACTAAGTTGTAAACAAATGG-30
Scan 2 263 50-CCCTTAGTGTTACACAACAGATCA-30 50-AAATTCATGACCTTTTGGACCT-30
Scan 3 263 50-TTAGGGAAAATTATGACGGTTTAT-30 50-CTTTCATCAGTAACAAAATAATTCAAA-30
Scan 4 310 50-TGCTAAATTTGCTTTGACTACTGA-30 50-AGCATCACGTCTCCAATAATGA-30
Scan 5 264 50-TCTGATTTAGATAAAGGTTTTACCCC-30 50-TTGACCACCCATAAGAATACCA-30
Scan 6 282 50-GGTGTGAAAATGACTGATCAAGA-30 50-TTTTCTAAAAATAGAATGTAATGGCA-30
Scan 7 274 50-CCATCAGTCAATAACACTATTAAGGAA-30 50-TCCCAAACCCATAATCAACTTC-30
Scan 8 274 50-TGCCAAAGCTAATTCTGTTTCA-30 50-TTTTTCCCAAATGATTTCTGCT-30
Scan 9 323 50-GCCTGACCCTGATTATAGTTCAA-30 50-AAATAACCAGTGGACAAAAACCAT-30
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Isolates Ca1V, Ca4V, Ca7V all were classified as vari-
ant 1. as they have the same characteristic HRM profile in
scan 3 (variant B) and in scan 6 (variant C), which was
unique among 9 isolates tested. Figure 1 shows an example
of HRM analysis. Scan 6 of ERG11 gene was amplified for
9 DNA samples and melting curves of PCR products were
Table 2 Antifungal drug
susceptibility of reference
strains and strains isolated from
vagina determined with
microdilution method
Strain Susceptibility of reference strains and vaginal isolates, IC50 (mg/l)
MIC KET ITR FCA AMB 5FC
Ca1r 0.0625 0.125 0.25 0.5 0.25 0.25
Ca1V 0.0625 0.125 0.25 0.25 0.5 1
Ca2V 0.0625 0.125 0.25 0.25 0.5 1
Ca3V 0.0625 0.0625 0.25 0.25 0.25 0.125
Ca4V 0.0625 0.25 0.5 0.5 0.5 1
Ca5V 0.5 2 16 64 0.25 1
Ca7V 0.0625 0.125 0.25 0.25 0.25 0.25
Ca11r 0.0625 0.125 0.5 0.5 0.25 0.125
Ca12r 0.0625 0.125 0.5 0.5 0.25 0.5
Table 3 Antifungal drug





















Table 4 Variants of scans and
ERG11 gene among reference
strains and vaginal isolates
identified by HRM analysis
Strain name Scan number Gene variants
1 2 3 4 5 6 7 8 9
Ca1r A A C C A B B C D ? 3.
Ca1V A A B B A C A A A ? 1.
Ca2V A A A A A A A B B ? 2.
Ca3V B A B0 B B B C A C ? 4.
Ca4V A A B B A C A A A ? 1.
Ca5V A A A A A A A B B ? 2.
Ca7V A A B B A C A A A ? 1.
Ca11r A A C B A B B C A ? 5.
Ca12r A A A A A A A B B ? 2.
A, B, C, D—variants of ERG11 gene fragments among each scan, B0—scan 3 variant not distinguishable by
means of HRM, 1–5—whole ERG11 sequence variants on the basis of scan variants
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analyzed. Normalized melting curve analysis showed three
variants of scan 6, which indicates differences in DNA
sequence among tested samples (Fig. 1).
Isolates Ca2V, Ca5V, and Ca12r were classified as
variant 2. of ERG11 gene as they represent unique pattern
of nine scans variants (Table 4). Here, scan 8 and scan 9
are those, which differentiate the samples from all isolates
as they are the only ones showing variant B in both ERG11
fragments.
Isolates Ca1r, Ca3V, and Ca11r were classified as
variant 3., 4. and 5. of ERG11 gene, respectively, and their
patterns of scans variants were unique among isolates
tested.
To confirm differences in DNA sequence identified by
HRM analysis, all DNA samples were amplified and
sequenced. Indeed, isolates Ca1V, Ca4V, Ca7V (variant 1)
had the same nucleotide sequence through whole ERG11
gene. Separate ERG11 variant was also found for Ca2V,
Ca5V, Ca12r isolates (variant 2). Isolates Ca1r, Ca3V and
Ca11r represent unique DNA sequence of ERG11.
Sequence of fragment 3 of Ca3V sample (B0) occurred to
be different from this part of Ca1V, Ca4V, Ca7V isolates,
but this difference could not be detected by means of
HRM. This difference in HRM and sequencing analysis is
due to the principle of HRM analysis. The fluorescence
signal comes from melting strands depending on their
nucleotide content but not on the order of nucleotides.
Thus, only by means of sequencing were we able to dif-
ferentiate variant B (thymine in position 315 to cytosine
and cytosine in position 411 to thymine—in strains Ca1V,
Ca4V, Ca7V) from variant B0 (cytosine in position 315 to
thymine and thymine in position 411 to cytosine—in strain
Ca3V).
Regarding the yeast susceptibility to azoles, two gene
variants (1 and 2) are related to increased drug resistance,
except for strain Ca7V which is susceptible to all tested
drugs. Strains numbered Ca1r, Ca3V, and Ca11r, having
unique ERG11 patterns, are the most susceptible ones.
Sequencing of ERG11 Gene Revealed Two Point
Mutations Associated with C. albicans Drug
Resistance
Sequencing was the method of choice for analysis of
ERG11 changes in C. albicans saliva strains. For ERG11
sequences of saliva strains the great majority of gene length
was successfully sequenced but some fragments of gene
were unreadable. The analysis of mutations in C. albicans
strains of all origins was performed with gPLINK and
Haploview software. Drug resistance and susceptibility of
strains tested were referred to point mutations in ERG11
using allelic model. Two intermediate saliva strains
(Ca21s, Ca68s) were classified as susceptible for allelic
frequency tests. Among 21 point mutations found within
ORFs, two were significantly associated with drug resis-
tance (Table 5). Odds ratio based on allelic frequency was
calculated in these two cases. Namely, nucleotide substi-
tution at 798 position (Glu266Asp) corresponds to increase
of drug resistance. Strains that possess mutated allele
variant are 4.7-fold (odds ratio = 4.7143; CI 95 %
1.2368–17.9700) more probable to be drug resistant. In
turn, mutation at 1440 position (Leu480Leu) significantly
decreases the chance of a strain to be drug resistant (odds
ratio = 0.11; CI 95 % 0.0127–0.9504).
Pairwise linkage disequilibrium (LD) and r2 plots were
generated on the basis of variants found in ERG11 gene
(Fig. 2a, b). Two blocks of mutations that are inherited
together with high frequency were identified. One block of
Fig. 1 HRM analysis of ERG11 gene-scan 6 of Candida albicans
reference strains and vaginal isolated. Both panels (a normalized melt
curve, b difference curve) show three variants of the analyzed gene
fragment among nine isolates tested indicating differences in DNA
sequences. Red curves variant A, green curves variant B, blue curves
variant C (Color figure online)
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strongly associated mutations comprised Asp116Glu,
Lys119Lys, Lys128Thr, Ser137Ser, and Val159Ile. Second
block contained Glu266Asp and Lys342Lys.
Sequencing of ERG11 gene revealed many heterozy-
gous and homozygous mutations but only four of them
changed amino acid sequence: D116E, K128T, V159I,
E266D (Table 6).
Discussion
Various mechanisms of drug resistance in C. albicans have
been studied in recent years. Various authors agree that
many different phenomena occurring simultaneously in a
yeast cell are responsible for gaining drug resistance by C.
albicans strains [7, 33, 40]. Mechanisms based on over-
expression or hyperactivity of CDR1, CDR2, and MDR1
efflux pumps have been widely investigated [2, 19, 27].
Promising, but not yet very common are other approaches
to the problem concerning mutations in CDR1 and CDR2
transcription factors [3], specific chromosome alterations
[37], and mutations in various ergosterol synthesis pathway
genes, like ERG5 or ERG3 [22]. Moreover, many genetic
studies indicate that mutations in ERG11 or overexpression
of these azole drugs target gene cause increased resistance
to commonly administered antifungal drugs [14, 31, 43].
In this study, we present the application of HRM method
to discriminate different variants of ERG11 gene in C.
albicans strains on the basis of single-nucleotide poly-
morphisms. Among nine strains tested, three isolates
Ca1V, Ca4V, Ca7V had the same variant of ERG11 gene
sequence. Characteristic pattern is composed by mutations
present in scan 3 and scan 6. Another distinctive sequence
was determined by HRM analysis for Ca2V, Ca5V, and
Ca12r isolates which represent variant 2 and their ERG11
gene sequence differs from other isolates in scan 8 and 9.
Three other variants of ERG11 gene sequence were unique
among strains tested. Sequence differences between vari-
ants were confirmed by sequencing reaction for all isolates
included in HRM analysis.
These results indicate that HRM analysis could be a
useful tool for classifying C. albicans isolates to distinctive
variants of ERG11 gene. Similar approach has been
described by Strzelczyk who used MSSCP method for
Table 5 Allele frequencies and
Chi-square test results for C.
albicans resistant (AFF) and
susceptible (UNAFF) strains
SNP A1 A2 Model AFF UNAFF CHISQ test P
UTR_up 2 4 ALLELIC 0/2 2/12 0.3265 0.5677
Phe105Phe 4 2 ALLELIC 14/16 19/21 0.004778 0.9449
Asp116Glu 1 4 ALLELIC 8/22 8/32 0.4321 0.511
Lys119Lys 3 1 ALLELIC 8/22 8/32 0.4321 0.511
Lys128Thr 2 1 ALLELIC 8/22 6/34 1.458 0.2272
Ser137Ser 2 4 ALLELIC 15/15 17/23 0.3886 0.5331
Val159Ile 1 3 ALLELIC 7/23 4/36 2.301 0.1293
His183His 2 4 ALLELIC 9/21 17/23 1.147 0.2841
Le220Leu 2 4 ALLELIC 6/24 11/29 0.5244 0.469
Glu266Asp 2 1 ALLELIC 9/7 6/22 5.495 0.01908*
Val332Val 4 2 ALLELIC 12/12 17/19 0.04449 0.8329
Leu340Leu 3 1 ALLELIC 0/24 2/34 1.379 0.2402
Lys342Lys 3 1 ALLELIC 10/14 11/25 0.7814 0.3767
Ser361Ser 3 1 ALLELIC 0/2 4/10 0.7619 0.3827
Leu370Leu 2 4 ALLELIC 11/13 13/23 0.5671 0.4514
Phe380Phe 2 4 ALLELIC 2/22 4/32 0.1235 0.7253
Tyr401Tyr 2 4 ALLELIC 0/2 6/8 1.371 0.2416
Asp428Asp 2 4 ALLELIC 0/2 4/10 0.7619 0.3827
Ala432Ala 4 2 ALLELIC 14/12 12/24 2.609 0.1063
Ala434Ala 2 4 ALLELIC 14/12 14/22 1.364 0.2429
Leu480Leu 3 1 ALLELIC 1/25 8/22 5.378 0.0204*
Asn490Asn 2 4 ALLELIC 1/25 6/24 3.323 0.06831
UTR_down 2 4 ALLELIC 1/1 6/8 0.03628 0.8489
One missense mutation (Glu266Asp) and one silent mutation (Leu480Leu) statistically significantly cor-
relate with drug resistance (P value\0.05, marked *)
SNP single-nucleotide polymorphism, A1 allele 1, A2 allele2; 1 adenine, 2 cytosine, 3 guanine, 4 thymine
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preliminary selection of isolates presenting differences in
ERG11 gene, prior to sequence analysis [36]. Rapid
detection of ERG11 mutations was also performed by
Loeffler et. [16] who used fluorescence resonance energy
transfer and probed melting curves for this purpose.
Another approach to determine ERG11 mutations consisted
in the use of padlock probe and rolling circle amplification
(RCA)-based method [39]. As the alternative to usual DNA
sequencing, bioluminometric pyrosequencing method was
employed to detect ERG11 mutations [10].
Considering low complexity of HRM reaction prepara-
tion and high resolution of analysis results, we propose
Fig. 2 Pairwise linkage
disequilibrium (LD) and r2 plot.
a Values on LD plot are
D0 9 100 and lack of value
indicates D0 = 1 9 100. Darker
background indicates greater
linkage. b Values on r2 plot are
r2 9 100, lack of value
indicates r2 = 1 9 100. Denser
color indicates greater linkage
(Color figure online)
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HRM analysis as an alternative method of sample selection
for subsequent sequencing. Nota bene, multi-well plate
format is used for HRM reaction, which gives the possi-
bility to predict mutations in tested sample using a panel of
ERG11 gene variants for HRM analysis prepared in
advance. Thus, HRM analysis should be seriously consid-
ered in attempts to accelerate diagnosis of Candida
infection.
Drug susceptibility tests revealed that one out of nine
strains was highly resistant to antifungal drugs (Ca5V) and
was also resistant to itraconazole and fluconazole accord-
ing to NCCLS breakpoints [26]. Five other strains pre-
sented increased resistance to at least one drug (Ca1V,
Ca4V, Ca2V, Ca11r, and Ca12r) and only three of them
were resistant to an azole drug. Namely, they were resistant
to itraconazole with MIC = 0.5 mg mL-1, which is clas-
sified as dose-dependent susceptibility (S-DD) according to
NCCLS.
In general, resistant strains represented variant 1. or
variant 2. of ERG11 gene sequence with the exception of
strain Ca11r, which was classified as distinct variant by
HRM and by sequencing. It suggests the existence of
another drug-resistance mechanism which causes slightly
increased resistance to itraconazole of Ca11r strain. It is
well documented that C. albicans strains develop many
different mechanisms of resistance to azole drugs simul-
taneously [7, 30]. Some authors also suggest that due to the
complexity of resistance in C. albicans it is necessary to
analyze groups of resistant and susceptible strains that are
matched, in order to reliably identify the mechanism
responsible for azole resistance [40]. Moreover, heteroge-
neous mechanisms of resistance may develop within clonal
origin subpopulations under azole exposure [23]. On the
other hand, several studies indicate that some ERG11 point
mutations may occur in azole susceptible, as well as in
resistant strains [21, 30, 40]. This is in line with our
observation in isolate Ca1V, Ca2V, and Ca7V that do not
show increased resistance to any azole drug, although
being members of variants 1 or 2. of ERG11, which we
initially considered characteristic for drug-resistant strains.
Thus, in order to correlate C. albicans drug resistance
with ERG11 gene variants using HRM method, it seems to
be important to primarily recognize single-nucleotide
polymorphism, which is related to increased resistance.
Then, it could be possible to design more exact HRM tests
with short fragments of ERG11 gene embracing statisti-
cally significant point mutations in ERG11 sequence. For
this purpose, a numerous group of C. albicans isolates are
needed. Here, we present ERG11 sequencing results for the
collection of 27 C. albicans strains isolated from saliva of
healthy volunteers. The statistical analysis was performed
for strains of all origins. Among them, 21 nucleotide sub-
stitutions were recognized, and two of them were associ-
ated with changes in drug resistance with statistical
significance (Chi square test, P\ 0.05). Strains that carry
substitution at position 798 (Glu266Asp) for at least one
allele are 4.7-fold more probable to be azole resistant. This
is in agreement with the results of Loffler who identified
Glu266Asp substitution in 5 out of 19 resistant strains [17].
None of 19 susceptible strains showed this mutation.






348 (scan 3) D116E TT Ca1r, Ca1V, Ca3V, Ca4V, Ca11r, Ca2s, Ca3s, Ca6s, Ca10s, Ca20s, Ca21s, Ca23s, Ca26s,
Ca38s, Ca40s, Ca41s, Ca44s, Ca68s, Ca74s, Ca80s, Ca81s, Ca82s
TA Ca2V, Ca5V, Ca6V, Ca12r, Ca1s, Ca22s, Ca25s, Ca36s, Ca52s, Ca59s, Ca61s
AA Ca11s, Ca69s, Ca70s
383 (scan 3) K128T AA Ca1r, Ca1V, Ca3V, Ca4V, Ca11s, Ca2s, Ca3s, Ca6s, Ca10s, Ca20s, Ca21s, Ca23s, Ca26s,
Ca38s, Ca40s, Ca41s, Ca44s, Ca68s, Ca70s, Ca74s, Ca80s, Ca81s, Ca82s
AC Ca2V, Ca5V, Ca6V, Ca12r, Ca1s, Ca22s, Ca25s, Ca36s, Ca52s, Ca59s, Ca61s
CC Ca11r, Ca69s
475 (scan 3) V159I GG Ca1r, Ca1V, Ca2V, Ca3V, Ca4V, Ca5V, Ca11s, Ca12r, Ca2s, Ca3s, Ca6s, Ca10s, Ca20s,
Ca21s, Ca23s, Ca26s, Ca38s, Ca40s, Ca41s, Ca44s, Ca68s, Ca70s, Ca74s, Ca80s, Ca81s,
Ca82s
AA Ca11r, Ca69s, Ca70s
AG Ca1s, Ca22s, Ca25s, Ca36s, Ca52s, Ca59s, Ca61s
798 (scan 5) E266D AA Ca1r, Ca1V, Ca2V, Ca4V, Ca5V, Ca11r, Ca12r, Ca10s, Ca11s, Ca22s, Ca52s, Ca61s, Ca69s
CC Ca3V, Ca3s, Ca23s, Ca40s, Ca41s, Ca44s
AC Ca74s, Ca80s, Ca81s
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However, many authors suggest that substitution is not
associated with resistance as it occurs in resistant, as well
as in susceptible strains [24, 40]. Glu266Asp amino acid
substitution was also shown not to be related to decreased
affinity of fluconazole to ERG11 gene product, cytochrome
P-450 [18]. Another substitution, which had statistical
significance, was silent mutation at position 1440
(Leu480Leu) which statistically decreases probability of
resistance in C. albicans strains. Nucleotide substitution at
this site was also found by others [22, 23]; however, to the
best of our knowledge no one have ever estimated its
significance in drug resistance prediction. The impact of
silent polymorphisms has been considered as a risk factor
in disease development of higher eukaryotic organisms
[34]. Silent mutations may cause structural and functional
changes in synthesized protein [12]. Many mechanisms of
this phenomena were proposed, one of which is change in
translation kinetics and altered protein folding [13]. Other
explanation may be that silent mutations cause native
splicing donor site inactivation [11]. This change would
shorten mRNA chain length of ERG11 and the usage of
RT-PCR could confirm this hypothesis in our study. It is
also possible that alternate splicing caused changed protein
or small RNA binding or synonymous SNPs changed
mRNA stability what consequently led to lower lanosterol
demethylase expression and decrease of yeast drug resis-
tance [32]. Also a polar effect to other gene can be con-
sidered, although it has only been shown for
Saccharomyces cerevisiae mutants [9]. Taking the above
into account, we suggest that silent mutations, frequently
occurring in ERG11 gene, should also be considered as
drug-resistance markers when establishing new genetic
prediction methods.
On the basis of the presented data, HRM analysis seems
to be a useful screening method that allows to select DNA
samples for subsequent sequencing of ERG11 gene, thus
cheapening and shortening the process of Candida infec-
tion diagnosis. However, it is not a reliable method of
classification of C. albicans resistant and susceptible
strains, firstly because other drug-resistance mechanisms
may occur simultaneously, and secondly because our
knowledge of changes in ERG11 responsible for azole
resistance is not yet sufficient to design proper and trust-
worthy test based on ERG11 mutation sites. Nevertheless,
the number of current studies on C. albicans drug resis-
tance increases, and they lead to better understanding of the
significance of ERG11 mutations, which makes scanning
methods like HRM analysis a promising tool for the future
diagnosis of C. albicans infections.
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